Intraoperative Detection of Cold Agglutinins During Cardiopulmonary Bypass in a Child

Samantha Vizzini, Hiromi Kako, Christopher McKee, Ashley Hodge, Joseph D. Tobias

Abstract

Cold agglutinins are auto-antibodies, usually of the IgM class, that are present in low titers in the blood of normal individuals. They are generally of no clinical significance in healthy patients because they are active only at extremely low temperatures (less than 10 °C). However, when present in high titers, during periods of hypothermia, they may have clinical impact. We present a child presenting for surgery for congenital heart disease, in whom blood agglutination was noted during hypothermia while on cardiopulmonary bypass (CPB). The history of cold agglutinin disease (CAD) is presented, typical clinical manifestations are discussed, and options for perioperative care including the conduct of CPB are presented.

Keywords: Cold agglutinins; Cardiopulmonary bypass; Congenital cardiac disease

Introduction

Cold agglutinins are auto-antibodies, usually of the IgM class, that are present in low titers in the blood of normal individuals. They are of no clinical significance in healthy patients because they are active only at extremely low temperatures (less than 10 °C). However, these antibodies can be found in higher titers, most commonly related to antecedent viral or mycoplasma infections [1, 2]. At these higher titers, the red blood cells (RBCs) may react at a broader range of temperatures and may result in clinical manifestations at 30 - 37 °C. We present a child presenting for surgery for congenital heart disease (CHD), in whom blood agglutination was noted during hypothermia while on cardiopulmonary bypass (CPB). The history of cold agglutinin disease (CAD) is presented, typical clinical manifestations are discussed, and options for perioperative care including the conduct of CPB are presented.

Case Report

IRB approval is not required for single patient case reports at Nationwide Children’s Hospital. A 12-year-old boy with a history of tetralogy of Fallot status-post repair at 4 months of age with a trans-annular patch of the right ventricular outflow tract presented for pulmonary valve replacement. Preoperative findings included severe right ventricular dilation and severe pulmonary regurgitation. A peripheral intravenous catheter was placed in the preoperative area and anxiolysis was achieved with intravenous midazolam and fentanyl. The patient was then transported to the operating room where standard Ameri-
can Society of Anesthesiologists’ monitors were applied. Prior to anesthetic induction, bilateral paravertebral blocks were placed in the sitting position with a total of 20 mL of 0.5% ropivacaine. The patient tolerated the procedure well and general anesthesia was subsequently induced followed by endotracheal intubation. A right internal jugular triple-lumen catheter was placed with ultrasound guidance as well as a right radial arterial line. The patient remained stable throughout both of these procedures. A time-out was performed and the surgical incision was made with median sternotomy. After adequate dissection and visualization was obtained, cannulation sutures were placed in the aorta and inferior and superior vena cava. A heparin loading dose of 400 IU/kg was administered and cannulation for CPB was performed. After adequate anticoagulation was established with a target activated clotting time (ACT) of 480 s with the HMS® Heparin Management System (Medtronic Inc., Minneapolis, MN, USA), CPB was initiated and full flow was achieved. The patient was then cooled to 34 °C. Twenty-four minutes after the initiation of cooling, the perfusionist alerted the surgeon for concerns of cold agglutination noted in the venous reservoir and oxygenator (Fig. 1). At that time, the decision was made to rewarm the patient to 36 °C and increase the fraction of inspired oxygen (FiO₂) to 100%. The patient remained stable throughout the procedure and neither pump flow nor pressures were altered by the reaction. After rewarming the patient, the agglutination reaction partially dissipated and the surgical repair was completed under normothermia. The patient was weaned from CPB. A cold agglutinin titer was sent after the termination of CPB; however, the results were non-diagnostic (see below). After completion of the procedure, the patient’s trachea was extubated in the operating room and he was transported to the cardiothoracic intensive care unit (CTICU). The remainder of his postoperative course was uneventful and the patient was discharged home on postoperative day 4.

Discussion

Two forms of cold antibody autoimmune hemolytic anemia have been identified including Donath-Landsteiner hemolytic anemia (DLHA) and CAD. DLHA is an intravascular hemolytic anemia caused by a cold-reacting immunoglobulin of the IgG which is usually directed at either the P or I antigen on the RBC surface. Most cases are due to polyclonal IgG, although IgM-induced DLHA has been described [1-3]. In contrast to DLHA, CAD is always due to a cold-reacting IgM antibody.

Investigations into the etiology of these disorders began as early as 1865, when cases of hemoglobinuria following exposure to cold were identified. Although Donath and Landsteiner first characterized the causative antibody and later described the presence of these antibodies in humans in studies comparing human and primate blood, the association between these antibodies, cold agglutination, and hemolysis was not described until 1937 [4-6]. Sir John Dacie published “The haemolytic anaemias” in 1966 which described 16 cases of CAD [7]. Dacie noted that cold agglutinins could be identified in both healthy patients and those with symptoms. The difference was the thermal amplitude of the cold agglutinins with healthy patients showing agglutination only at temperatures below 4 °C compared to symptomatic patients who agglutinated at temperatures as high as 37 °C.

CAD is a subtype of autoimmune hemolytic anemia which involves IgM antibodies which are active at cold temperatures and directed against surface antigens of RBCs. CAD may either be primary/idiopathic or secondary to another disease process such as lymphoma or infections including Mycoplasma pneumoniae. Typically, the idiopathic form presents in patients over the age of 50 with no reported cases in pediatric patients [1]. Patients may be asymptomatic or present with acrocyanosis, chest pain, abdominal pain, or Raynaud’s phenomenon. Occasionally patients present with odynophagia when eating cold food.

The understanding of the pathophysiology of this disease has greatly improved in the past 20 years. The antibodies involved are generally low in titer and only active at extremely low temperatures in the majority of patients and therefore clinically insignificant. However, during cardiac surgery when cooling is required for cardiac and neurologic protection, significant problems may be noted even in patients with relatively low antibody titers. Antibodies bind to RBC membranes in the periphery where the temperature is low causing agglutination and activation of the complement system. Once the complement system is activated, C3 convertase cleaves C3 into C3a and C3b, which binds to RBC membranes and serves as a target for tissue macrophages and extravascular hemolysis [8]. As RBCs recirculate to the warmer core of the body, IgM dissociates from the RBCs and the agglutinated RBCs separate from each other. However, C3b remains on the surface of the RBC leading to sequestration and destruction in the liver leading to anemia, hematuria, microthrombi and in severe cases, circulatory collapse.

It is not standard practice to test specifically for these antibodies prior to cardiac surgery because they cannot be detected with standard antibody screening and the incidence of clinically significant titers is low. The specific test for CAD is a quantitative assay which is run only in specific reference laboratories. Stringent rules must be followed for collection and transport of the sample to the lab. Blood must be collected in warmed tubes and kept in a 37 °C water bath. This allows the antibodies to dissociate from the RBCs and back into the plasma. Once the sample arrives at the hospital laboratory, it is allowed to clot at 37 °C and then spun down to separate the serum from the RBCs. Only the serum is sent to the outside lab for antibody detection. Therefore if temperature regulations are not strictly followed, there will be no antibodies to detect in the serum as they will remain bound to the patient’s RBCs. Antibody titers ≥ 1:32 are considered a positive result. In the past, with a positive antibody titer, thermal amplitudes were previously calculated to determine at what temperature agglutination would occur. Recently this appears to have fallen out of favor, and if laboratories obtain a positive result, a qualitative assay is performed to determine the type of immunoglobulin involved. Unfortunately, in our patient, it appears that these strict parameters for care of the blood test were not followed and as such, it is possible that a false negative test resulted. As
our patient is clinically asymptomatic and does not appear to need further cardiac surgery, we do not plan to retest him at this time.

Clinical management of patients with CAD has previously consisted of cold avoidance, corticosteroid therapy, plasmapheresis, and even exchange transfusion. Given their invasive nature, techniques such as plasmapheresis or exchange transfusion, are only recommended when there is no option other than deep hypothermia for specific surgical procedures. In the past 30 years, there have been several advancements in the understanding of the pathology and immune basis for this disease leading to improvements in treatment options. Silberstein et al studied patients with lymphoma induced and idiopathic cold agglutinins and found a monoclonal defect in B-cell lymphocytes in both patient populations which has served as a target for immuno-modulating drug therapy in recent years [9]. His work has identified a specific cell line of B-cell lymphocytes which may allow specific therapy with rituximab, a chimeric monoclonal antibody against the protein CD20, which may allow specific therapy with rituximab, a chimeric monoclonal antibody against the protein CD20, which may allow specific therapy with rituximab, a chimeric monoclonal antibody against the protein CD20. These monoclonal antibodies have been associated with improvements in treatment options.

As occurred in our patient, there are several anecdotal reports of CAD being diagnosed intraoperatively with problems occurring being noted during hypothermia and CPB including intracoronary thrombosis, incomplete cardioplegia delivery, agglutination within the circuit, and high pressures in the CPB circuit [10-13]. Other authors have previously reported suggestions for the perioperative management during the care of patients with CAD (Table 1) [14-18]. When CAD follows an infectious etiology, elective and non-urgent procedures should be postponed as the antibody titer can be expected to decline over 4 - 8 weeks. In general, maintenance of normothermia is essential with forced air warming of the patient [16]. Such therapy may be instituted preoperatively when the patient is known to have CAD [19]. Additionally, intraoperative warming and humidification of inspired gases as well as intravenous fluids may be indicated. Irrigation fluids should also be warmed and any exposed organs may be wrapped in warm packs to prevent evaporative heat loss. Prevention of a cold agglutination reaction in cardiac surgical patients may require warming all fluids including the CPB circuit as well as the cardioplegia solution. In specific cases, warm cardioplegia may be required [9]. The patient’s body temperature should be kept several degrees above the thermal amplitude of the antibody if that is known. Allogeneic blood products should be avoided if possible as the donor RBCs will be free of C3d fragments [8]. C3d is a degradation product of C3b that coats RBCs after further hemolysis.

Table 1. Previous Reports of Anesthesia for Patients With Cold Agglutinins

<table>
<thead>
<tr>
<th>Authors and reference</th>
<th>Patient demographics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aoki et al [16]</td>
<td>A 76-year-old male with idiopathic cold hemagglutinin disease for myocardial revascularization.</td>
</tr>
<tr>
<td>Beebe et al [17]</td>
<td>An 82-year-old, 60 kg female with idiopathic cold hemagglutinin disease for splenectomy and cholecystectomy.</td>
</tr>
<tr>
<td>Bracken et al [18]</td>
<td>1) A 67-year-old male with type 2 diabetes mellitus, hypertension, and coronary artery disease for coronary revascularization.  2) A 54-year-old male with triple-vessel coronary artery disease for myocardial revascularization.</td>
</tr>
</tbody>
</table>

References

4. Donath J, Landsteiner K. Ueber das Phanomen der Autoagglutination und uber die Eigenscaften der Kalteha-